94 results on '"Kristensen, Søren L."'
Search Results
2. Association of multiple sclerosis with incident diabetes: A nationwide cohort study
- Author
-
Jacobsen, Jeppe Ravn, Kristensen, Søren L., Fosbøl, Emil L., Køber, Lars, Westergaard, Lucas Malta, Persson, Frederik, Rossing, Peter, and Rørth, Rasmus
- Published
- 2024
- Full Text
- View/download PDF
3. Long-Term Medical Treatment and Adherence in Patients With Left Ventricular Assist Devices: A Danish Nationwide Cohort Study
- Author
-
Schjødt, Inge, Mols, Rikke E., Eiskjær, Hans, Bakos, István, Horváth-Puhó, Erzsébet, Gustafsson, Finn, Kristensen, Søren L., Larsson, Johan E., and Løgstrup, Brian B.
- Published
- 2023
- Full Text
- View/download PDF
4. Hemodialysis and its impact on patient characteristics, microbiology, cardiac surgery, and mortality in infective endocarditis
- Author
-
Stahl, Anna, Havers-Borgersen, Eva, Østergaard, Lauge, Petersen, Jeppe K., Bruun, Niels E., Weeke, Peter E., Kristensen, Søren L., Voldstedlund, Marianne, Køber, Lars, and Fosbøl, Emil L.
- Published
- 2023
- Full Text
- View/download PDF
5. Patient characteristics and long-term outcomes in patients undergoing transcatheter aortic valve implantation in a failed surgical prosthesis vs in a native valve: A Danish nationwide study
- Author
-
Begun, Xenia, Butt, Jawad H., Kristensen, Søren L., Weeke, Peter E., De Backer, Ole, Strange, Jarl E., Schou, Morten, Køber, Lars, and Fosbøl, Emil L.
- Published
- 2023
- Full Text
- View/download PDF
6. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial
- Author
-
Lee, Matthew M.Y., Kristensen, Søren L., Gerstein, Hertzel C., McMurray, John J.V., and Sattar, Naveed
- Published
- 2022
- Full Text
- View/download PDF
7. Socio‐economic position, multimorbidity, and health care utilization among Danish left ventricular assist device patients.
- Author
-
Schjødt, Inge, Mols, Rikke E., Bakos, István, Horváth‐Puhó, Erzsébet, Gustafsson, Finn, Kristensen, Søren L., Larsson, Johan E., Christensen, Bo, Eiskjær, Hans, and Løgstrup, Brian B.
- Subjects
MEDICAL care ,MEDICAL care use ,GENERAL practitioners ,MEDICAL prescriptions ,MEDICAL registries ,HEART assist devices - Abstract
Aims: Increasing numbers of patients with advanced heart failure and significant comorbidity and social barriers are considered for left ventricular assist devices (LVADs). We sought to examine health care utilization post‐LVAD implantation, including the influence of individual‐level socio‐economic position and multimorbidity. Methods and results: We conducted a Danish nationwide cohort study linking individual‐level data from clinical LVAD databases, the Scandiatransplant Database, and Danish national medical and administrative registries. Socio‐economic position included cohabitation status, educational level, and employment status. Multimorbidity was defined as two or more chronic conditions from at least two chronic disease groups. Health care utilization (hospital activity, general practice activity, and redeemed medical prescriptions) within 2 years post‐discharge after LVAD implantation was evaluated using descriptive statistics at 0.5 year intervals. We identified 119 patients discharged alive with first‐time LVAD implanted between 2006 and 2018. The median age of the patients was 56.1 years, and 88.2% were male. Patients were followed until heart transplantation, LVAD explantation, death, 31 December 2018, or for 2 years. The median follow‐up was 0.8 years. The highest median use of health care services was observed 0–0.5 years post‐LVAD discharge compared with the subsequent follow‐up intervals: 0.5–1, 1–1.5, and 1.5–2 years, respectively. The median (interquartile range) number of hospitalizations was 10 (7–14), bed days 14 (9–28), outpatient visits 8 (5–12), telephone contacts with a general practitioner 4 (2–8), and total redeemed medical prescriptions 26 (19–37) within 0–0.5 years post‐LVAD discharge compared with the median utilization within the consecutive follow‐up periods [e.g. within 0.5–1 year: hospitalizations 5 (3–8), bed days 8 (4–14), outpatient visits 5 (3–8), telephone contacts 2 (0–5), and redeemed medical prescriptions 24 (18–30)]. The median use of health care services was stable from 0.5 years onwards. The median number of hospitalizations and bed days was slightly higher in patients living alone with a low educational level or low employment status within 0–0.5 years post‐LVAD implantation. Finally, the median number of in‐hospital days and redeemed prescriptions was higher among patients with pre‐existing multimorbidity. Conclusions: Among patients who underwent LVAD implantation, health care utilization was high in the early post‐LVAD discharge phase and was influenced by socio‐economic position. Multimorbidity influenced the number of in‐hospital days and redeemed prescriptions during the 2 year follow‐up. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- Author
-
Sattar, Naveed, Lee, Matthew M Y, Kristensen, Søren L, Branch, Kelley R H, Del Prato, Stefano, Khurmi, Nardev S, Lam, Carolyn S P, Lopes, Renato D, McMurray, John J V, Pratley, Richard E, Rosenstock, Julio, and Gerstein, Hertzel C
- Published
- 2021
- Full Text
- View/download PDF
9. Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus
- Author
-
Yafasova, Adelina, Fosbøl, Emil L., Schou, Morten, Baslund, Bo, Faurschou, Mikkel, Docherty, Kieran F., Jhund, Pardeep S., McMurray, John J.V., Sun, Guoli, Kristensen, Søren L., Torp-Pedersen, Christian, Køber, Lars, and Butt, Jawad H.
- Published
- 2021
- Full Text
- View/download PDF
10. Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis
- Author
-
Sigvardt, Flora L., Hansen, Morten L., Kristensen, Søren L., Gustafsson, Finn, Ghanizada, Muzhda, Schou, Morten, Køber, Lars, Torp-Pedersen, Christian, Gislason, Gunnar H., and Madelaire, Christian
- Published
- 2020
- Full Text
- View/download PDF
11. Association of carpal tunnel syndrome with incident diabetes.
- Author
-
Jacobsen, Jeppe Ravn, Westergaard, Lucas Malta, Fosbøl, Emil L., Kristensen, Søren L., Køber, Lars, Persson, Frederik, Rossing, Peter, and Rørth, Rasmus
- Subjects
CARPAL tunnel syndrome ,ACE inhibitors ,ANGIOTENSIN-receptor blockers ,TYPE 2 diabetes ,PERSONAL identification numbers ,TYPE 1 diabetes - Abstract
This article, published in the journal Diabetes, Obesity & Metabolism, discusses a study that examines the connection between carpal tunnel syndrome (CTS) and the development of diabetes. The study used data from Danish nationwide registries to compare patients who had surgery for CTS with a control group from the general population. The findings indicate that individuals with CTS have a higher risk of developing diabetes compared to the control group. The study emphasizes the importance of early detection and intervention for better outcomes. However, other factors like obesity and glycated hemoglobin levels may also influence this relationship. Further research is needed to fully understand the connection between CTS and diabetes. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
12. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- Author
-
Kristensen, Søren L, Rørth, Rasmus, Jhund, Pardeep S, Docherty, Kieran F, Sattar, Naveed, Preiss, David, Køber, Lars, Petrie, Mark C, and McMurray, John J V
- Published
- 2019
- Full Text
- View/download PDF
13. Burden and Causes of Hospital Admissions in Heart Failure During the Last Year of Life
- Author
-
Madelaire, Christian, Gustafsson, Finn, Kristensen, Søren L., D’Souza, Maria, Stevenson, Lynne W., Kober, Lars, Torp-Pedersen, Christian, Gislason, Gunnar, and Schou, Morten
- Published
- 2019
- Full Text
- View/download PDF
14. Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study
- Author
-
Larsson, Johan, Kristensen, Søren L., Madelaire, Christian, Schou, Morten, Rossing, Kasper, Boesgaard, Søren, Køber, Lars, and Gustafsson, Finn
- Published
- 2021
- Full Text
- View/download PDF
15. Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study
- Author
-
Madelaire, Christian, Gislason, Gunnar, Kristensen, Søren L., Fosbøl, Emil L., Bjerre, Jenny, D’Souza, Maria, Gustafsson, Finn, Kober, Lars, Torp-Pedersen, Christian, and Schou, Morten
- Published
- 2018
- Full Text
- View/download PDF
16. Return to the workforce following coronary artery bypass grafting: A Danish nationwide cohort study
- Author
-
Butt, Jawad H., Rørth, Rasmus, Kragholm, Kristian, Kristensen, Søren L., Torp-Pedersen, Christian, Gislason, Gunnar H., Køber, Lars, and Fosbøl, Emil L.
- Published
- 2018
- Full Text
- View/download PDF
17. Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure
- Author
-
Rørth, Rasmus, Fosbøl, Emil L., Mogensen, Ulrik M., Kragholm, Kristian, Jhund, Pardeep S., Petrie, Mark C., Schou, Morten, Gislason, Gunnar H., McMurray, John J.V., Torp-Pedersen, Christian, Køber, Lars, and Kristensen, Søren L.
- Published
- 2018
- Full Text
- View/download PDF
18. Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis
- Author
-
Wong, Chih M., Hawkins, Nathaniel M., Ezekowitz, Justin A., Jhund, Pardeep S., Savu, Anamaria, MacDonald, Michael R., Kristensen, Søren L., Petrie, Mark C., McMurray, John J.V., McAlister, Finlay A., and Kaul, Padma
- Published
- 2017
- Full Text
- View/download PDF
19. Mortality in heart failure with and without autoimmune disease.
- Author
-
Sun, Guoli, Faurschou, Mikkel, Vinding, Naja E, Yafasova, Adelina, Kristensen, Søren L, Ahlehoff, Ole, Schou, Morten, Fosbøl, Emil L, Køber, Lars, and Butt, Jawad H
- Published
- 2023
- Full Text
- View/download PDF
20. Trends in Medical and Device Therapies Following Incident Heart Failure in Denmark during 1996–2019: A Nationwide Register-Based Follow-Up Study.
- Author
-
Ettrup-Christensen, Asbjørn, Butt, Jawad H., Andersen, Mikkel Porsborg, Sessa, Maurizio, Polcwiartek, Christoffer, Fosbøl, Emil L., Rørth, Rasmus, Kristensen, Søren L., Torp-Pedersen, Christian, Køber, Lars, Schou, Morten, Tayal, Bhupendar, Søgaard, Peter, and Kragholm, Kristian
- Published
- 2023
- Full Text
- View/download PDF
21. Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
- Author
-
Kristensen, Søren L., Jhund, Pardeep S., Lee, Matthew M. Y., Køber, Lars, Solomon, Scott D., Granger, Christopher B., Yusuf, Salim, Pfeffer, Marc A., Swedberg, Karl, McMurray, John J. V., and CHARM Investigators and Committees
- Published
- 2017
- Full Text
- View/download PDF
22. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status
- Author
-
Kristensen, Søren L., Mogensen, Ulrik M., Jhund, Pardeep S., Rørth, Rasmus, Anand, Inder S., Carson, Peter E., Desai, Akshay S., Pitt, Bertram, Pfeffer, Marc A., Solomon, Scott D., Zile, Michael R., Køber, Lars, and McMurray, John J. V.
- Published
- 2019
- Full Text
- View/download PDF
23. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro–B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
- Author
-
Kristensen, Søren L., Jhund, Pardeep S., Køber, Lars, McKelvie, Robert S., Zile, Michael R., Anand, Inder S., Komajda, Michel, Cleland, John G.F., Carson, Peter E., and McMurray, John J.V.
- Published
- 2015
- Full Text
- View/download PDF
24. The New Pooled Cohort Equations Risk Calculator
- Author
-
Preiss, David and Kristensen, Søren L.
- Published
- 2015
- Full Text
- View/download PDF
25. Ventricular rate in atrial fibrillation and the risk of heart failure and death.
- Author
-
Westergaard, Lucas Malta, Alhakak, Amna, Rørth, Rasmus, Fosbøl, Emil L, Kristensen, Søren L, Svendsen, Jesper H, Graff, Claus, Nielsen, Jonas B, Gislason, Gunnar H, Køber, Lars, Torp-Pedersen, Christian, Lee, Christina J Y, and Weeke, Peter E
- Abstract
Aims While clinical trials have suggested that a high ventricular rate is associated with increased risk of heart failure (HF) and mortality, all-comers studies are warranted. Objective To assess 1-year risk of new-onset diagnosed HF and all-cause mortality among rate-control treated patients presenting with atrial fibrillation (AF) on an electrocardiogram (ECG) according to ventricular rate. Methods and results ECGs recorded at the Copenhagen General Practitioners Laboratory (2001–15) were used to identify patients with AF. Multivariate Cox proportional hazard regression models were used to compare risk of new-onset HF and all-cause mortality after first ECG presenting with AF according to ventricular rate on ECG [<60, 60–79, 80–99, and 100–110, > 110 beats per minute (bpm)]. We identified 7408 patients in treatment with rate control drugs at time of first ECG presenting with AF [median age 78 years (Q1,Q3 = 70–85 years)], 45.8% male, median ventricular rate 83 bpm, (Q1,Q3 = 71–101 bpm)]. During 1-year follow-up, 666 (9.0%) of all patients with AF developed HF and 858 (11.6%) died. Patients with AF ventricular rates 100–110 bpm and >110 bpm had a hazard ratio (HR) of 1.46 (CI: 1.10–1.95) and 2.41 (CI: 1.94–3.00) respectively for new-onset HF, compared with 60–79 bpm. Similarly, patients with AF ventricular rates 100–110 bpm and >110 bpm had a HR of 1.44 (CI: 1.13–1.82) and 1.34 (CI: 1.08–1.65) respectively for all-cause mortality, compared with 60–79 bpm. Conclusions Ventricular rates ≥100 bpm among patients presenting with AF on ECG in treatment with rate control drugs were associated with greater risk of both new-onset HF and all-cause mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction
- Author
-
Lamberts, Morten, Fosbøl, Emil L., Olsen, Anne-Marie S., Hansen, Morten L., Folke, Frederik, Kristensen, Søren L., Olesen, Jonas B., Hansen, Peter R., Køber, Lars, Torp-Pedersen, Christian, and Gislason, Gunnar H.
- Published
- 2013
- Full Text
- View/download PDF
27. SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place.
- Author
-
Kristensen, Søren L., Jensen, Jesper, and Schou, Morten
- Subjects
- *
CHRONIC kidney failure , *SODIUM-glucose cotransporter 2 inhibitors , *HEART failure patients - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Return to work after acute myocardial infarction with cardiogenic shock: a Danish nationwide cohort study.
- Author
-
Lauridsen, Marie D, Rørth, Rasmus, Butt, Jawad H, Schmidt, Morten, Weeke, Peter E, Kristensen, Søren L, Møller, Jacob E, Hassager, Christian, Kjærgaard, Jesper, Torp-Pedersen, Christian, Gislason, Gunnar, Køber, Lars, and Fosbøl, Emil L
- Published
- 2022
- Full Text
- View/download PDF
29. Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation.
- Author
-
Vinding, Naja E., Kristensen, Søren L., Rørth, Rasmus, Butt, Jawad H., Østergaard, Lauge, Olesen, Jonas B., Pedersen, Christian Torp, Gislason, Gunnar H., Køber, Lars, Kruuse, Christina, Johnsen, Søren P., Fosbøl, Emil L., and Torp-Pedersen, Christian
- Published
- 2022
- Full Text
- View/download PDF
30. Long-term prognosis following hospitalization for acute myocarditis – a matched nationwide cohort study.
- Author
-
Ghanizada, Muzhda, Kristensen, Søren L., Bundgaard, Henning, Rossing, Kasper, Sigvardt, Flora, Madelaire, Christian, Gislason, Gunnar H., Schou, Morten, Hansen, Morten L., and Gustafsson, Finn
- Subjects
- *
HEART failure , *PROGNOSIS , *MYOCARDITIS , *MORTALITY , *COHORT analysis , *VENTRICULAR ejection fraction - Abstract
The aim of this study was to examine the long-term risk of heart failure (HF) and all-cause mortality, in patients discharged alive following hospitalization for myocarditis. Background. Prognosis in patients with apparently uncomplicated myocarditis is in general perceived as good, but data on long-term outcomes are sparse. Methods. From nationwide Danish registries we included patients without prior cardiac disease, discharged alive with a first-time diagnosis of myocarditis 1996–2016. Patients were matched 1:10 by age- and sex, with controls from the general population. Risk of HF hospitalization and death in cases and controls was compared by use of adjusted Cox regression analyses. Results. We identified 1557 patients with a first-time diagnosis of myocarditis, 72% men, median age 39 years. Patients with myocarditis had more hypertension, diabetes, and cancer, and received more pharmacotherapy prior to hospitalization compared to matched controls. During a mean follow-up of 8.5 years, the event rate of HF hospitalization was 8.7 vs. 2.2 per 1000 patient-years (py) in cases and controls; HR 4.59 (95% CI; 3.58–5.88) and for all-cause mortality, event rate 21.9 vs 11.2 per 1000 py; HR 2.10 (95% CI; 1.82–2.43). Among 784 patients with no events or HF medication one year after diagnosis, risk of HF hospitalization (HR 2.15; 95% CI; 1.18–3.92), and all-cause mortality (HR 1.62; 95% CI; 1.21–2.16) remained elevated compared to matched controls. Conclusion. Myocarditis in younger patients without prior cardiac disease was associated with a long-term excess risk of HF hospitalization, and death, even in patients free of events and HF medication 1 year after discharge. Myocarditis ranges from chest discomfort to severe heart failure. In most patients, left ventricular ejection fraction recovers but the long-term adverse cardiac risk is unknown. Patients with myocarditis and no prior cardiac disease were at higher risk of death and heart failure Routine follow-up may be warranted following an episode of acute myocarditis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. The effect of sodium‐glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies.
- Author
-
Krogh, Jesper, Hjorthøj, Carsten, Kristensen, Søren L., Selmer, Christian, and Haugaard, Steen B.
- Subjects
CARDIOVASCULAR disease related mortality ,SODIUM-glucose cotransporters ,SCIENTIFIC observation ,MORTALITY ,BIBLIOGRAPHY ,RANDOMIZED controlled trials ,TYPE 2 diabetes ,TREATMENT effectiveness ,SOCIOECONOMIC factors ,HOSPITAL care ,BIBLIOGRAPHICAL citations ,RESEARCH bias ,HEART failure - Abstract
Aim: Randomized clinical trials (RCTs) allocating type 2 diabetes patients to treatment with sodium‐glucose transport protein 2 (SGLT‐2) inhibitors or placebo have found significant effects on the risk of heart failure and modest effects on mortality. In the wake of the first trials, a number of observational studies have been conducted, some of these reporting a mortality reduction of 50% compared to active comparators. In this review, we systematically assess and compare the results on all‐cause mortality, cardiovascular mortality and heart failure hospitalization observed in RCTs with the results obtained in observational studies. Method: We performed a systematic bibliographical search including cardiovascular outcome trials and observational studies assessing the effect of SGLT‐2 inhibitors on mortality and heart failure. Results: Seven RCTs and 23 observational studies were included in the current review. The observed heterogeneity between study results for all‐cause mortality (p‐interaction < 0.001) and cardiovascular mortality (p‐interaction < 0.001) was explained by study type, whereas this was not the case for heart failure (p‐interaction = 0.18). Conclusion: Methodological considerations such as the omission of important confounders, immortal‐time bias and residual confounding such as unmeasured social economic inequality may be the cause of the inflated results observed in observational studies and that calls for caution when observational studies are used to guide treatment of patients with type 2 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer.
- Author
-
Rørth, Rasmus, Clausen, Marianne F., Fosbøl, Emil L., Mogensen, Ulrik M., Kragholm, Kristian, Jhund, Pardeep S., Petrie, Mark C., Torp-Pedersen, Christian, Gislason, Gunnar H., McMurray, John J. V., Køber, Lars, and Kristensen, Søren L.
- Subjects
NURSING care facilities ,OBSTRUCTIVE lung diseases ,NURSING home care ,HEART failure ,HEART failure patients ,DISEASE risk factors - Abstract
Background: Patients with chronic diseases are at higher risk of requiring domiciliary and nursing home care, but how different chronic diseases compare in terms of risk is not known. We examined initiation of domiciliary care and nursing home admission among patients with heart failure (HF), stroke, COPD and cancer. Methods: Patients with a first-time hospitalization for HF, stroke, COPD or cancer from 2008–2016 were identified. Patients were matched on age and sex and followed for five years. Results: 111,144 patients, 27,786 with each disease, were identified. The median age was 69 years and two thirds of the patients were men. The 5-year risk of receiving domiciliary care was; HF 20.9%, stroke 25.2%, COPD 24.6% and cancer 19.3%. The corresponding adjusted hazard ratios (HRs), with HF patients used as reference, were: stroke 1.35[1.30–1.40]; COPD 1.29[1.25–1.34]; and cancer 1.19[1.14–1.23]. The five-year incidence of nursing home admission was 6.6% for stroke, and substantially lower in patients with HF(2.6%), COPD(2.6%) and cancer (1.5%). The adjusted HRs were (HF reference): stroke, 2.44 [2.23–2.68]; COPD 1.01 [0.91–1.13] and cancer 0.76 [0.67–0.86]. Living alone, older age, diabetes, chronic kidney disease, depression and dementia predicted a higher likelihood of both types of care. Conclusions: In patients with HF, stroke, COPD or cancer 5-year risk of domiciliary care and nursing home admission, ranged from 19–25% and 1–7%, respectively. Patients with stroke had the highest rate of domiciliary care and were more than twice as likely to be admitted to a nursing home, compared to patients with the other conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease.
- Author
-
Malik, Mariam E., Madelaire, Christian, D'Souza, Maria, Blanche, Paul, Kristensen, Søren L., Kistorp, Caroline, Gustafsson, Finn, Køber, Lars, Rørth, Rasmus, McMurray, John, Sattar, Naveed, Gislason, Gunnar, Torp‐Pedersen, Christian, Schou, Morten, and Torp-Pedersen, Christian
- Subjects
CHRONIC kidney failure ,TYPE 2 diabetes ,HEART diseases ,COMPETING risks ,RESEARCH ,MYOCARDIAL ischemia ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,HEART failure ,DISEASE complications - Abstract
Aims: To evaluate the risk of heart failure (HF) in patients with type 2 diabetes (T2D) complicated by development of intercurrent ischaemic heart disease (IHD), end-stage renal disease (ESRD), or both, compared to patients with T2D and no IHD and ESRD.Methods and Results: From Danish nationwide registries, we identified all patients with new-onset T2D with no history of HF between 1998 and 2015. Landmark analyses were used to estimate the 5-year absolute risk of HF at several follow-up times, and accounted for the occurrence of IHD and ESRD, identified before HF. The Aalen-Johansen estimator was used to account for censoring and the competing risk of death. A total of 285 024 patients with new-onset T2D were included. During follow-up, 19 960 developed incident HF. Among patients with T2D free of HF 5 years after T2D diagnosis, patients without IHD and ESRD had the lowest 5-year risk of HF [4.02%; 95% confidence interval (CI) 3.90-4.15), those with T2D complicated by IHD [11.51%; relative risk (RR) 2.86; 95% CI 2.72-3.02; P < 0.001] or ESRD (8.11%; RR 2.02; 95% CI 1.39-2.93; P < 0.001) an intermediate risk, and those with both IHD and ESRD (19.76%; RR 4.92; 95% CI 3.43-7.05; P < 0.001) the highest risk.Conclusion: Patients with T2D complicated by development of intercurrent IHD, ESRD, or both, showed a significantly higher risk of HF compared to those who did not develop IHD and ESRD. An effective way to delay or prevent the development of HF in patients with T2D may be to prevent IHD and ESRD. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
34. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
- Author
-
Cannon, Jane A., Shen, Li, Jhund, Pardeep S., Kristensen, Søren L., Køber, Lars, Chen, Fabian, Gong, Jianjian, Lefkowitz, Martin P., Rouleau, Jean L., Shi, Victor C., Swedberg, Karl, Zile, Michael R., Solomon, Scott D., Packer, Milton, McMurray, John J.V., Kristensen, Søren L, Køber, Lars, and PARADIGM-HF Investigators and Committees
- Subjects
HEART failure treatment ,VENTRICULAR ejection fraction ,NEPRILYSIN ,ANGIOTENSIN receptors ,COGNITION ,ACE inhibitors ,AMINOBUTYRIC acid ,HETEROCYCLIC compounds ,ENALAPRIL ,AMNESIA ,COGNITION disorders ,COMPARATIVE studies ,DELIRIUM ,DEMENTIA ,HEART failure ,HYPERSOMNIA ,RESEARCH methodology ,MEDICAL cooperation ,PROTEOLYTIC enzymes ,RESEARCH ,RESEARCH funding ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,PROPORTIONAL hazards models ,STROKE volume (Cardiac output) ,CHEMICAL inhibitors ,THERAPEUTICS - Abstract
Aims: Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM-HF which compared the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan with enalapril. As neprilysin is also one of many enzymes clearing amyloid-β peptides from the brain, there is a theoretical concern about the long-term effects of sacubitril/valsartan on cognition. Therefore, we have examined dementia-related adverse effects (AEs) in PARADIGM-HF and placed these findings in the context of other recently conducted HFrEF trials.Methods and Results: In PARADIGM-HF, patients with symptomatic HFrEF were randomized to sacubitril/valsartan 97/103 mg b.i.d. or enalapril 10 mg b.i.d. in a 1:1 ratio. We systematically searched AE reports, coded using the Medical Dictionary for Regulatory Activities (MedDRA), using Standardized MedDRA Queries (SMQs) with 'broad' and 'narrow' preferred terms related to dementia. In PARADIGM-HF, 8399 patients aged 18-96 years were randomized and followed for a median of 2.25 years (up to 4.3 years). The narrow SMQ search identified 27 dementia-related AEs: 15 (0.36%) on enalapril and 12 (0.29%) on sacubitril/valsartan [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.33-1.59]. The broad search identified 97 (2.30%) and 104 (2.48%) AEs (HR 1.01, 95% CI 0.75-1.37), respectively. The rates of dementia-related AEs in both treatment groups in PARADIGM-HF were similar to those in three other recent trials in HFrEF.Conclusion: We found no evidence that sacubitril/valsartan, compared with enalapril, increased dementia-related AEs, although longer follow-up may be necessary to detect such a signal and more sensitive tools are needed to detect lesser degrees of cognitive impairment. Further studies to address this question are warranted. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
35. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.
- Author
-
Rørth, Rasmus, Thune, Jens Jakob, Nielsen, Jens C, Haarbo, Jens, Videbæk, Lars, Korup, Eva, Signorovitch, James, Bruun, Niels E, Eiskjær, Hans, Hassager, Christian, Svendsen, Jesper Hastrup, Høfsten, Dan E, Torp-Pedersen, Christian, Pehrson, Steen, Køber, Lars, and Kristensen, Søren L
- Abstract
Aims: Implantable cardioverter-defibrillator (ICD) implantation reduce the risk of sudden cardiac death, but not all-cause death in patients with non-ischaemic systolic heart failure (HF). Whether co-existence of diabetes affects ICD treatment effects is unclear.Methods and Results: We examined the effect of ICD implantation on risk of all-cause death, cardiovascular death, and sudden cardiac death (SCD) according to diabetes status at baseline in the Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischaemic Systolic Heart Failure on Mortality (DANISH) trial. Outcomes were analysed by use of cumulative incidence curves and Cox regressions models. Of the 1116 patients enrolled, 211 (19%) had diabetes at baseline. Patients with diabetes were more obese, had worse kidney function and more were in New York Heart Association Class III/IV. The risk of device infections and other complications in the ICD group was similar among patients with and without diabetes (6.1% vs. 4.6% P = 0.54). Irrespective of treatment group, diabetes was associated with higher risk of all-cause death, cardiovascular death, and SCD. The treatment effect of ICD in patients with diabetes vs. patients without diabetes was hazard ratio (HR) = 0.92 (0.57-1.50) vs. HR = 0.85 (0.63-1.13); Pinteraction = 0.60 for all-cause mortality, HR = 0.99 (0.58-1.70) vs. HR = 0.70 (0.48-1.01); Pinteraction = 0.25 for cardiovascular death, and HR = 0.81 (0.35-1.88) vs. HR = 0.40 (0.22-0.76); Pinteraction = 0.16 for sudden cardiac death.Conclusion: Among patients with non-ischaemic systolic HF, diabetes was associated with higher incidence of all-cause mortality, primarily driven by cardiovascular mortality including SCD. Treatment effect of ICD therapy was not significantly modified by diabetes which might be due to lack of power. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
36. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
- Author
-
Rørth, Rasmus, Jhund, Pardeep S., Kristensen, Søren L., Desai, Akshay S., Køber, Lars, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., Packer, Milton, and McMurray, John J.V.
- Subjects
BRAIN natriuretic factor ,HEART failure ,HEART ,TYPE 2 diabetes complications ,DISEASES ,LONGITUDINAL method ,TYPE 2 diabetes ,PEPTIDE hormones ,PEPTIDES ,PROGNOSIS ,TROPONIN ,STROKE volume (Cardiac output) ,DISEASE complications - Abstract
Aims: We examined the prognostic importance of N-terminal pro B-type natriuretic peptide (NT-proBNP) and troponin T (TnT) in heart failure patients with and without diabetes.Methods and Results: We measured NT-proBNP and TnT in the biomarker substudy of the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Of 1907 patients, 759 (40%) had diabetes. Median TnT in patients with diabetes was 18 (interquartile range 11-27) ng/L and 13 (9-21) ng/L in those without (P < 0.001). The TnT frequency-distribution curve was shifted to the right in patients with diabetes, compared to those without diabetes. By contrast, NT-proBNP did not differ between patients with and without diabetes. Diabetes and each biomarker were predictive of worse outcomes. Thus, patients with diabetes, an elevated TnT and a NT-proBNP level in the highest tertile (9% of all patients) had an absolute risk of cardiovascular death or heart failure hospitalization of 265 per 1000 person-years, compared to a rate of 42 per 1000 person-years in those without diabetes, a TnT < 18 ng/L and a NT-proBNP in the lowest tertile (16% of all patients). TnT remained an independent predictor of adverse outcomes in multivariable analyses including NT-proBNP.Conclusion: TnT is elevated to a greater extent in heart failure patients with diabetes compared to those without (whereas NT-proBNP is not). TnT and NT-proBNP are additive in predicting risk and when combined help identify diabetes patients at extremely high absolute risk. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
37. Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial.
- Author
-
Kristensen, Søren L., Rørth, Rasmus, Jhund, Pardeep S., Shen, Li, Lee, Matthew M. Y., Petrie, Mark C., Køber, Lars, McMurray, John J.V., and BEST Investigators
- Subjects
- *
PEOPLE with diabetes , *HEART failure patients , *ADRENERGIC beta blockers , *MICROCIRCULATION disorders , *CAUSES of death , *COMPARATIVE studies , *DIABETIC angiopathies , *HEART failure , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *SURVIVAL , *TIME , *EVALUATION research , *RANDOMIZED controlled trials , *DISEASE incidence , *BLIND experiment , *RETROSPECTIVE studies , *STROKE volume (Cardiac output) , *DISEASE complications - Abstract
Aims: The role of microvascular complications in the risk conferred by diabetes in heart failure with reduced ejection fraction (HFrEF) is unknown.Methods and Results: We studied 2707 HFrEF patients in the Beta-blocker Evaluation of Survival Trial (BEST), stratified into three groups: no diabetes and diabetes without or with microvascular complications (neuropathy, nephropathy, or retinopathy). The risks of the composite of cardiovascular death or heart failure hospitalization, and all-cause death, were studied using Cox regression analyses adjusted for other prognostic variables. Overall, 964 (36%) patients had diabetes, of which 313 (32%) had microvascular complications. Patients with microvascular complications had more severe symptoms (New York Heart Association class IV 12% vs. 9% diabetes with no complications and 7% no diabetes), and worse quality of life (Minnesota Living with Heart Failure median score 60 vs. 54 and 51 points). In patients with diabetes and complications, the rate of the composite outcome was 50 per 100 person-years of follow-up (compared with 34 and 29 in those with diabetes and no microvascular complications and participants without diabetes, respectively). Compared to patients without diabetes, the adjusted hazard ratio (HR) for the composite outcome was 1.44 [95% confidence interval (CI) 1.22-1.70] and 1.18 (95% CI 1.03-1.35) for patients with diabetes with and without complications, respectively. The risk of all-cause mortality was similarly elevated: adjusted HR 1.42 (95% CI 1.16-1.74) and 1.20 (95% CI 1.01-1.42), respectively.Conclusion: In HFrEF, diabetes with microvascular complications is associated with worse symptoms and outcomes than diabetes without microvascular complications. Prevention of microvascular complications has the potential to improve HFrEF outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
38. Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study.
- Author
-
Rørth, Rasmus, Fosbøl, Emil L, Kragholm, Kristian, Mogensen, Ulrik M, Jhund, Pardeep S, Petrie, Mark C, Torp-Pedersen, Christian, Gislason, Gunnar H, McMurray, John JV, Køber, Lars, and Kristensen, Søren L
- Subjects
HEART failure patients ,HEART failure risk factors ,QUALITY of life measurement ,NURSING home care ,COHORT analysis - Abstract
Background: Heart failure (HF) has a major impact on a patient's quality of life and functional status. This impact may be sufficiently profound to prevent independent living although how often this is the case is unknown. We examined the need for domiciliary assistance and admission to a nursing home following first HF hospitalization. Methods: In nationwide Danish registries, we identified a cohort of patients discharged alive after a first-time HF hospitalization in the period 2008–2014 who were matched 1:5 with comparison subjects based on age and sex and followed for 5 years. Results: We included 37,547 patients (69% men) discharged after a first-time HF-hospitalization and 187,735 comparison subjects. The 5-year incidence of initiation of domiciliary care was 24.1% [23.7%–24.6%] among HF patients and 9.2% [9.1%–9.4%] among the comparison cohort and yielded a corresponding adjusted HR of 2.02 [1.96–2.09]. Covariates associated with initiation of domiciliary support included older age (HR 1.08 [1.07–1.08] per 1 year increase in age), living alone (HR 2.09 [2.04–2.15]) and comorbidities. The 5-year incidence of nursing home admission was 3.9% [3.7%–4.0%] among HF patients and 1.7% [1.7%–1.8%] among the comparison cohort and this resulted in an adjusted HR of 1.91 [1.77–2.06]. Covariates associated with nursing home admission included older age (HR 1.10 [1.10–1.11]), living alone (HR 2.15 [2.02–2.28]) and history of stroke (HR 2.71 [2.53–2.90]). Conclusion: Hospitalization for HF is associated with increased need for domiciliary support and nursing home admissions. Older age, living alone, and comorbidities were associated with higher risk of both outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
39. Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction.
- Author
-
Rørth, Rasmus, Jhund, Pardeep S., Mogensen, Ulrik M., Kristensen, Søren L., Petrie, Mark C., Køber, Lars, and McMurray, John J. V.
- Subjects
HEART failure ,HEART diseases ,DIABETES risk factors ,TYPE 2 diabetes ,CARDIOVASCULAR diseases ,MYOCARDIAL infarction ,ENDOCRINE diseases ,HEART ventricle diseases ,LEFT heart ventricle ,COMORBIDITY ,DISEASE incidence - Abstract
Objective: Although diabetes is well known to be common in prevalent heart failure (HF) and portends a poor prognosis, the role of diabetes in the development of incident HF is less well understood. We studied the role of diabetes in the transition from asymptomatic left ventricular systolic dysfunction (ALVSD) to overt HF in the prevention arm of the Studies of Left Ventricular Dysfunction (SOLVD-P).Research Design and Methods: We examined the development of symptomatic HF, HF hospitalization, and cardiovascular death according to diabetes status at baseline in patients in SOLVD-P. These outcomes were analyzed by using cumulative incidence curves and Cox regression models adjusted for age, sex, and other prognostic factors, including randomized treatment, HF severity, and comorbidity.Results: Of the 4,223 eligible participants, 647 (15%) had diabetes at baseline. Patients with diabetes were older and had a higher average weight, systolic blood pressure, and heart rate. During the median follow-up of 36 months, 861 of the 3,576 patients without diabetes (24%) developed HF compared with 214 of the 647 patients with diabetes (33%). In unadjusted analyses, patients with diabetes had a higher risk of development of HF (hazard ratio 1.53 [95% CI 1.32-1.78]; P < 0.001), HF hospitalization (2.04 [1.65-2.52]; P < 0.0001), and the composite outcome of development of HF or cardiovascular death (1.48 [1.30-1.69]; P < 0.001). The effect of enalapril on outcomes was not modified by diabetes status.Conclusions: In patients with ALVSD, diabetes is associated with an increased risk of developing HF. Development of HF is associated with an increased risk of death irrespective of diabetes status. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
40. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
- Author
-
Mogensen, Ulrik M., Køber, Lars, Jhund, Pardeep S., Desai, Akshay S., Senni, Michele, Kristensen, Søren L., Dukát, Andrej, Chen, Chen‐Huan, Ramires, Felix, Lefkowitz, Martin P., Prescott, Margaret F., Shi, Victor C., Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Packer, Milton, McMurray, John J. V., on behalf of the PARADIGM‐HF Investigators and Committees, Chen, Chen-Huan, and PARADIGM-HF Investigators and Committees
- Subjects
URIC acid ,CARDIOVASCULAR diseases ,HEALTH outcome assessment ,HEART failure ,GLOMERULAR filtration rate ,ENTRESTO - Abstract
Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. We examined the association between SUA and outcomes as well as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF.Methods and Results: The association between SUA and the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization, its components, and all-cause mortality was examined using Cox regression analyses among 8213 patients using quintiles (Q1-Q5) of SUA adjusted for baseline prognostic variables including estimated glomerular filtration rate (eGFR), diuretic dose, and log N-terminal pro-brain natriuretic peptide. Change in SUA from baseline over 12 months was also evaluated in each treatment group. Patients in Q5 (SUA ≥8.6 mg/dL) compared with Q1 (<5.4 mg/dL) were younger (62.8 vs. 64.2 years), more often male (88.7% vs. 63.1%), had lower systolic blood pressure (119 vs. 123 mmHg), lower eGFR (57.4 vs. 76.6 mL/min/1.73 m2 ), and greater diuretic use. Higher SUA was associated with a higher risk of the primary outcome (adjusted hazard ratios) Q5 vs. Q1 = 1.28 [95% confidence intervals (1.09-1.50), P = 0.003], cardiovascular death [1.44 (1.11-1.77), P = 0.001], HF hospitalization [1.37 (1.11-1.70), P = 0.004], and all-cause mortality [1.36 (1.13-1.64), P = 0.001]. Compared with enalapril, sacubitril/valsartan reduced SUA by 0.24 (0.17-0.32) mg/dL over 12 months (P < 0.0001). Sacubitril/valsartan improved outcomes, irrespective of SUA concentration.Conclusion: Serum uric acid concentration was an independent predictor of worse outcomes after multivariable adjustment in patients with HFrEF. Compared with enalapril, sacubitril/valsartan reduced SUA and improved outcomes irrespective of SUA. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
41. Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure.
- Author
-
Rørth, Rasmus, Fosbøl, Emil L., Mogensen, Ulrik M., Kragholm, Kristian, Numé, Anna-karin, Gislason, Gunnar H., Jhund, Pardeep S., Petrie, Mark C., McMurray, John J. V., Torp-Pedersen, Christian, Køber, Lars, and Kristensen, Søren L.
- Subjects
MORTALITY risk factors ,AGE distribution ,EMPLOYMENT ,HEART failure ,HOSPITAL care ,LABOR supply ,OBSTRUCTIVE lung diseases ,REGRESSION analysis ,SEX distribution ,COMORBIDITY ,EDUCATIONAL attainment ,TREATMENT effectiveness ,PROPORTIONAL hazards models ,PATIENT readmissions ,ODDS ratio - Abstract
Aims Employment status at time of first heart failure (HF) hospitalization may be an indicator of both self-perceived and objective health status. In this study, we examined the association between employment status and the risk of all-cause mortality and recurrent HF hospitalization in a nationwide cohort of patients with HF. Methods and results We identified all patients of working age (18-60 years) with a first HF hospitalization in the period 1997-2015 in Denmark, categorized according to whether or not they were part of the workforce at time of the index admission. The primary outcome was death from any cause and the secondary outcome was readmission for HF. Cumulative incidence curves, binomial regression and Cox regression models were used to assess outcomes. Of 25 571 patients with a first hospitalization for HF, 15 428 (60%) were part of the workforce at baseline. Patients in the workforce were significantly younger (53 vs. 55 years) more likely to bemale (75% vs 64%) and less likely to have diabetes (13% vs 22%) and chronic obstructive pulmonary disease (5% vs 10%) (all P <0.0001). Not being part of the workforce was associated with a significantly higher risk of death [hazard ratio (HR) 1.59; 95% confidence interval (CI) 1.50-1.68] and rehospitalization for HF (HR 1.09; 95% CI 1.05-1.14), in analyses adjusted for age, sex, co-morbidities, education level, calendar time, and duration of first HF hospitalization. Conclusion Not being part of the workforce at time of first HF hospitalization was independently associated with increased mortality and recurrent HF hospitalization. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
42. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial.
- Author
-
Kristensen, Søren L., Mogensen, Ulrik M., Tarnesby, Georgia, Gimpelewicz, Claudio R., Ali, Mohammed A., Shao, Qing, Chiang, YannTong, Jhund, Pardeep S., Abraham, William T., Dickstein, Kenneth, McMurray, John J. V., and Køber, Lars
- Subjects
- *
HEART failure treatment , *ALISKIREN , *ENALAPRIL , *HEALTH outcome assessment , *ADVERSE health care events , *PEOPLE with diabetes , *THERAPEUTICS , *AMIDES , *ACE inhibitors , *COMBINATION drug therapy , *CLINICAL trials , *COMPARATIVE studies , *CAUSES of death , *DIABETES , *DOSE-effect relationship in pharmacology , *HEART failure , *ANTIHYPERTENSIVE agents , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *SURVIVAL , *EVALUATION research , *BLIND experiment , *ACYCLIC acids , *STROKE volume (Cardiac output) , *DISEASE complications - Abstract
Aims: Because of concerns about the safety of aliskiren in patients with diabetes, study treatment was stopped prematurely in the Aliskiren Trial of Minimizing OutcomeS for Patients with HEart failuRE (ATMOSPHERE). We examined outcomes and treatment effect in these patients compared with those without diabetes.Methods and Results: ATMOSPHERE included 7016 patients with heart failure and a reduced ejection fraction (HFrEF) randomly assigned to enalapril plus aliskiren, aliskiren alone, or enalapril. At baseline, 1944 (27.7%) patients had diabetes. Median follow-up was shorter in patients with diabetes compared with those without (24 months vs. 46 months). Among patients with diabetes, the primary endpoint of cardiovascular death or hospitalization for heart failure occurred in 216 patients (33.1%) in the enalapril group (reference), 172 (27.4%) in the aliskiren group [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.67-1.00; P = 0.053], and 196 (29.5%) in the combination group (HR 0.86, 95% CI 0.71-1.04; P = 0.13). The effects of the treatments studied did not differ significantly compared with patients without diabetes. In patients with diabetes, aliskiren monotherapy was associated with a lower risk of symptomatic hypotension compared to enalapril [42 (6.7%) vs. 65 (10.0%); P = 0.04], whereas other adverse events were generally balanced between the three groups.Conclusion: In patients with HFrEF and diabetes, there was no signal of harm and a trend towards benefit when direct renin inhibition monotherapy was compared with an angiotensin-converting enzyme inhibitor, whereas combined aliskiren and enalapril treatment led to more adverse events with no improvement in outcomes. Treatment effects did not differ in patients with diabetes compared with those without. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00853658. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
43. Return to the workforce following infective endocarditis-A nationwide cohort study.
- Author
-
Butt, Jawad H., Kragholm, Kristian, Dalager-Pedersen, Michael, Rørth, Rasmus, Kristensen, Søren L., Chaudry, Mavish S., Valeur, Nana, Østergaard, Lauge, Torp-Pedersen, Christian, Gislason, Gunnar H., Køber, Lars, and Fosbøl, Emil L.
- Abstract
Background: The ability to return to work after infective endocarditis (IE) holds important socioeconomic consequences for both patients and society, yet data on this issue are sparse. We examined return to the workforce and associated factors in IE patients of working age.Methods: Using Danish nationwide registries, we identified 1,065 patients aged 18-60 years with a first-time diagnosis of IE (1996-2013) who were part of the workforce prior to admission and alive at discharge.Results: One year after discharge, 765 (71.8%) patients had returned to the workforce, 130 (12.2%) were on paid sick leave, 76 (7.1%) received disability pension, 23 (2.2%) were on early retirement, 65 (6.1%) had died, and 6 (0.6%) had emigrated. Factors associated with return to the workforce were identified using multivariable logistic regression. Younger age (18-40 vs 56-60 years; odds ratio, 2.85; 95% CI, 1.71-4.76) and higher level of education (higher educational level vs basic school; 5.47, 2.05-14.6) and income (highest quartile vs lowest; 3.17, 1.85-5.46) were associated with return to the workforce. Longer length of hospital stay (>90 vs 14-30 days; 0.16, 0.07-0.38); stroke during IE admission (0.38, 0.21-0.71); and a history of chronic kidney disease (0.29, 0.11-0.75), chronic obstructive pulmonary disease (0.31, 0.13-0.71), and malignancy (0.39, 0.22-0.69) were associated with a lower likelihood of returning to the workforce.Conclusions: Seven of 10 patients who were part of the workforce prior to IE and alive at discharge were part of the workforce 1 year later. Younger age, higher socioeconomic status, and absence of major comorbidities were associated with return to the workforce. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
44. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
- Author
-
Mogensen, Ulrik M., Køber, Lars, Kristensen, Søren L., Jhund, Pardeep S., Gong, Jianjian, Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Swedberg, Karl, Zile, Michael R., Solomon, Scott D., Packer, Milton, McMurray, John J.V., and PARADIGM-HF Investigators and Committees
- Abstract
Background: Angiotensin converting enzyme inhibitors (ACE-I), are beneficial both in heart failure with reduced ejection fraction (HF-REF) and after myocardial infarction (MI). We examined the effects of the angiotensin-receptor neprilysin inhibitor sacubitril/valsartan, compared with the ACE-I enalapril, on coronary outcomes in PARADIGM-HF.Methods and Results: We examined the effect of sacubitril/valsartan compared with enalapril on the following outcomes: i) the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, ii) a pre-defined broader composite including, in addition, MI, stroke, and resuscitated sudden death, and iii) a post hoc coronary composite of CV-death, non-fatal MI, angina hospitalization or coronary revascularization. At baseline, of 8399 patients, 3634 (43.3%) had a prior MI and 4796 (57.1%) had a history of any coronary artery disease. Among all patients, compared with enalapril, sacubitril/valsartan reduced the risk of the primary outcome (HR 0.80 [0.73-0.87], P<.001), the broader composite (HR 0.83 [0.76-0.90], P<.001) and the coronary composite (HR 0.83 [0.75-0.92], P<.001). Although each of the components of the coronary composite occurred less frequently in the sacubitril/valsartan group, compared with the enalapril group, only CV death was reduced significantly.Conclusions: Compared with enalapril, sacubitril/valsartan reduced the risk of both the primary endpoint and a coronary composite outcome in PARADIGM-HF. Additional studies on the effect of sacubitril/valsartan on atherothrombotic outcomes in high-risk patients are merited. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
45. Syncope and Its Impact on Occupational Accidents and Employment: A Danish Nationwide Retrospective Cohort Study.
- Author
-
Numé, Anna-Karin, Kragholm, Kristian, Carlson, Nicolas, Kristensen, Søren L., Bøggild, Henrik, Hlatky, Mark A., Torp-Pedersen, Christian, Gislason, Gunnar, and Ruwald, Martin H.
- Subjects
SYNCOPE diagnosis ,AGE distribution ,CARDIOVASCULAR diseases ,MENTAL depression ,EMPLOYMENT ,HOSPITAL care ,WORK-related injuries ,INDUSTRIAL hygiene ,RISK assessment ,COMORBIDITY ,SYNCOPE ,EDUCATIONAL attainment ,DISEASE incidence ,ACQUISITION of data ,RETROSPECTIVE studies ,THERAPEUTICS - Abstract
Background: First-time syncopal episodes usually occur in adults of working age, but their impact on occupational safety and employment remains unknown. We examined the associations of syncope with occupational accidents and termination of employment.Methods and Results: Through linkage of Danish population-based registers, we included all residents 18 to 64 years from 2008 to 2012. Among 3 410 148 eligible individuals, 21 729 with a first-time diagnosis of syncope were identified, with a median age 48.4 years (first to third quartiles, 33.0-59.5), and 10 757 (49.5%) employed at time of the syncope event. Over a median follow-up of 3.2 years (first to third quartiles, 2.0-4.5), 622 people with syncope had an occupational accident requiring hospitalization (2.1/100 person-years). In multiple Poisson regression analysis, the incidence rate ratio in the employed syncope population was higher than in the employed general population (1.44; 95% confidence interval [CI], 1.33-1.55) and more pronounced in people with recurrences (2.02; 95% CI, 1.47-2.78). The 2-year risk of termination of employment was 31.3% (95% CI, 30.4%-32.3%), which was twice the risk of the reference population (15.2%; 95% CI, 14.7%-15.7%), using the Aalen-Johansen estimator. Factors associated with termination of employment were age <40 years (incidence rate ratio, 1.48; 95% CI, 1.37-1.59), cardiovascular disease (1.20; 95% CI, 1.06-1.36), depression (1.72; 95% CI, 1.55-1.90), and low educational level (2.61; 95% CI, 2.34-2.91).Conclusions: In this nationwide cohort, syncope was associated with a 1.4-fold higher risk of occupational accidents and a 2-fold higher risk of termination of employment compared with the employed general population. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
46. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
- Author
-
Kristensen, Søren L., Mogensen, Ulrik M., Jhund, Pardeep S., Petrie, Mark C., Win, Sithu, Køber, Lars, McKelvie, Robert S., Zile, Michael R., Anand, Inder S., Komajda, Michel, Gottdiener, John S., Carson, Peter E., McMurray, John J. V., and Preiss, David
- Subjects
- *
HEART failure , *VENTRICULAR ejection fraction , *HEART diseases , *BLOOD flow measurement , *DIABETES , *TYPE 2 diabetes diagnosis , *HETEROCYCLIC compounds , *TYPE 2 diabetes complications , *BIPHENYL compounds , *CARDIOVASCULAR diseases , *COMPARATIVE studies , *ECHOCARDIOGRAPHY , *HEART ventricles , *HOSPITAL care , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PEPTIDE hormones , *PEPTIDES , *RESEARCH , *EVALUATION research , *BODY mass index , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *DISEASE incidence , *PROPORTIONAL hazards models , *STROKE volume (Cardiac output) , *THERAPEUTICS - Abstract
Background: In patients with heart failure and preserved ejection fraction, little is known about the characteristics of, and outcomes in, those with and without diabetes mellitus.Methods: We examined clinical and echocardiographic characteristics and outcomes in the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) according to history of diabetes mellitus. Cox regression models were used to estimate hazard ratios for cardiovascular outcomes adjusted for known predictors, including age, sex, natriuretic peptides, and comorbidity. Echocardiographic data were available in 745 patients and were additionally adjusted for in supplementary analyses.Results: Overall, 1134 of 4128 patients (27%) had diabetes mellitus. Compared with those without diabetes mellitus, they were more likely to have a history of myocardial infarction (28% versus 22%), higher body mass index (31 versus 29 kg/m2), worse Minnesota Living With Heart Failure score (48 versus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320 pg/mL; all P<0.01), more signs of congestion, but no significant difference in left ventricular ejection fraction. Patients with diabetes mellitus had a greater left ventricular mass and left atrial area than patients without diabetes mellitus. Doppler E-wave velocity (86 versus 76 cm/s; P<0.0001) and the E/e' ratio (11.7 versus 10.4; P=0.010) were higher in patients with diabetes mellitus. Over a median follow-up of 4.1 years, cardiovascular death or heart failure hospitalization occurred in 34% of patients with diabetes mellitus versus 22% of those without diabetes mellitus (adjusted hazard ratio, 1.75; 95% confidence interval, 1.49-2.05), and 28% versus 19% of patients with and without diabetes mellitus died (adjusted hazard ratio, 1.59; confidence interval, 1.33-1.91).Conclusions: In heart failure with preserved ejection fraction, patients with diabetes mellitus have more signs of congestion, worse quality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosis. They also display greater structural and functional echocardiographic abnormalities. Further investigation is needed to determine the mediators of the adverse impact of diabetes mellitus on outcomes in heart failure with preserved ejection fraction and whether they are modifiable.Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
47. Return to the Workforce After First Hospitalization for Heart Failure: A Danish Nationwide Cohort Study.
- Author
-
Rørth, Rasmus, Fosbøl, Emil L., Køber, Lars, Mogensen, Ulrik M., Kristensen, Søren L., Chih Wong, Petrie, Mark C., Jhund, Pardeep S., McMurray, John J. V., Kragholm, Kristian, Lamberts, Morten, Gislason, Gunnar H., Gerds, Thomas A., Torp-Pedersen, Christian, and Wong, Chih
- Published
- 2016
- Full Text
- View/download PDF
48. Risk Related to Pre--Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction.
- Author
-
Kristensen, Søren L., Preiss, David, Jhund, Pardeep S., Squire, Iain, Cardoso, José Silva, Merkely, Bela, Martinez, Felipe, Starling, Randall C., Desai, Akshay S., Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., McMurray, John J. V., and Packer, Milton
- Abstract
Background--The prevalence of pre-diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known. We investigated these in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. Methods and Results--We examined clinical outcomes in 8399 patients with heart failure and reduced ejection fraction according to history of diabetes mellitus and glycemic status (baseline hemoglobin A1c [HbA1c]: <6.0% [<42 mmol/ mol], 6.0%-6.4% [42-A7 mmol/mol; pre-diabetes mellitus], and ≥6.5% [≥48 mmol/mol; diabetes mellitus]), in Cox regression models adjusted for known predictors of poor outcome. Patients with a history of diabetes mellitus (n=2907 [35%]) had a higher risk of the primary composite outcome of heart failure hospitalization or cardiovascular mortality compared with those without a history of diabetes mellitus: adjusted hazard ratio, 1.38; 95% confidence interval, 1.25 to 1.52; P<0.001. HbA1c measurement showed that an additional 1106 (13% of total) patients had undiagnosed diabetes mellitus and 2103 (25%) had pre-diabetes mellitus. The hazard ratio for patients with undiagnosed diabetes mellitus (HbA1c, >6.5%) and known diabetes mellitus compared with those with HbA1c<6.0% was 1.39 (1.17-1.64); P<0.001 and 1.64 (1.43-1.87); P<0.001, respectively. Patients with pre-diabetes mellitus were also at higher risk (hazard ratio, 1.27 [1.10-1.47]; P<0.001) compared with those with HbA1c<6.0%. The benefit of LCZ696 (sacubitril/valsartan) compared with enalapril was consistent across the range of HbA1c in the trial. Conclusions--In patients with heart failure and reduced ejection fraction, dysglycemia is common and pre-diabetes mellitus is associated with a higher risk of adverse cardiovascular outcomes (compared with patients with no diabetes mellitus and HbA1c <6.0%). LCZ696 was beneficial compared with enalapril, irrespective of glycemic status. Clinical Trial Registration--URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
49. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.
- Author
-
Kristensen, Søren L., Jhund, Pardeep S., Køber, Lars, Preiss, David, Kjekshus, John, McKelvie, Robert S., Zile, Michael R., Anand, Inder S., Wikstrand, John, Wedel, Hans, Komajda, Michel, Carson, Peter E., Cleland, John G.F., and McMurray, John J.V.
- Subjects
- *
HOSPITAL patients , *HEART failure patients , *MYOCARDIAL infarction , *STROKE , *HEART failure , *HEART disease related mortality , *HEALTH outcome assessment , *HOSPITAL care , *PROGNOSIS - Abstract
Aims To investigate the prognostic significance of hospitalization for worsening heart failure ( WHF), myocardial infarction ( MI), and stroke in patients with chronic heart failure ( HF). Methods and results We studied 5011 patients with HF and reduced EF ( HF-REF) in the CORONA trial and 4128 patients with HF and preserved EF ( HF-PEF) in the I-Preserve trial. Adjusted hazard ratios ( HRs) for death were estimated for 0-30 days and ≥31 days after first post-randomization WHF, MI, or stroke used as a time-dependent variable, compared with patients with none of these events. In CORONA, 1616 patients (32%) had post-randomization first events (1223 WHF, 216 MI, 177 stroke), and the adjusted HR for mortality ≤30 days after an event was: WHF 7.21 [95% confidence interval ( CI) 2.05-25.40], MI 23.08 (95% CI 6.44-82.71), and stroke 32.15 (95% CI 8.93-115.83). The HR for mortality at >30 days was: WHF 3.62 (95% CI 3.11-4.21), MI 4.41 (95% CI 3.23-6.02), and stroke 3.19 (95% CI 2.21-4.61). In I-Preserve, 896 patients (22%) experienced a post-randomization event (638 WHF, 111 MI, 147 stroke). The HR for mortality ≤30 days was WHF 31.77 (95% CI 7.60-132.81), MI 154.77 (95% CI 34.21-700.17), and stroke 223.30 (95% CI 51.42-969.78); for >30 days it was WHF 3.36 (95% CI 2.79-4.05), MI 3.29 (95% CI 2.14-5.06), and stroke 5.13 (95% CI 3.61-7.29). Conclusions In patients with both HF-REF and HF-PEF, hospitalization for WHF was associated with high early and late mortality. The early relative risk of death was not as great as following MI or stroke, but the longer term relative risk of death was similar following all three types of event. Numerically, more deaths occurred following WHF because it was a much more common event. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
50. International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction.
- Author
-
Kristensen, Søren L., Køber, Lars, Jhund, Pardeep S., Solomon, Scott D., Kjekshus, John, McKelvie, Robert S., Zile, Michael R., Granger, Christopher B., Wikstrand, John, Komajda, Michel, Carson, Peter E., Pfeffer, Marc A., Swedberg, Karl, Wedel, Hans, Yusuf, Salim, and McMurray, John J. V.
- Subjects
- *
HEART failure , *HEALTH outcome assessment , *CLINICAL trials , *HOSPITAL care ,HEART disease research - Abstract
Background--International geographic differences in outcomes may exist for clinical trials of heart failure and reduced ejection fraction (HF-REF), but there are few data for those with preserved ejection fraction (HF-PEF). Methods and Results--We analyzed outcomes by international geographic region in the Irbesartan in Heart Failure with Preserved systolic function trial (I-Preserve), the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved trial, the CHARM-Alternative and CHARM-Added HF-REF trials, and the Controlled Rosuvastatin Multinational Trial in HF-REF (CORONA). Crude rates of heart failure hospitalization varied by geographic region, and more so for HF-PEF than for HF-REF. Rates in patients with HF-PEF were highest in the United States/Canada (HF hospitalization rate 7.6 per 100 patient-years in I-Preserve; 8.8 in CHARM-Preserved), intermediate in Western Europe (4.8/100 and 4.7/100), and lowest in Eastern Europe/Russia (3.3/100 and 2.8/100). The difference between the United States/Canada versus Eastern Europe/Russia persisted after adjustment for key prognostic variables: adjusted hazard ratios 1.34 (95% confidence interval, 1.01-1.74; P=0.04) in I-Preserve and 1.85 (95% confidence interval, 1.17-2.91; P=0.01) in CHARM-Preserved. In HF-REF, rates of HF hospitalization were slightly lower in Western Europe compared with other regions. For both HF-REF and HF-PEF, there were few regional differences in rates of all-cause or cardiovascular mortality. Conclusions--The differences in event rates observed suggest there is international geographic variation in 1 or more of the definition and diagnosis of HF-PEF, the risk profile of patients enrolled, and the threshold for hospitalization, which has implications for the conduct of future global trials. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.